Abstract
DanShen is a Chinese medicine that is used to treat cardiovascular disorders. DanShen is moderately to strongly protein bound, mainly to albumin. Because impaired protein binding of albumin‐bound drugs in uremia has been reported, we studied protein binding of DanShen by measuring the digoxin‐like immunoreactive component of this Chinese medicine. We observed a significantly higher percentage of free fraction of DanShen in uremic sera in vitro. Impaired protein binding of DanShen was also observed in sera from patients with liver disease, who had elevated concentrations of bilirubin. Treating uremic sera with activated charcoal significantly improved the protein binding of DanShen, indicating that uremic compounds are responsible for the impaired protein binding of DanShen. On the other hand, when various amounts of bilirubin were added to aliquots of the normal pool supplemented with DanShen, we observed only a modest displacement of DanShen from the protein‐binding sites by bilirubin, indicating that hypoalbuminemia may play a major role in impaired protein binding of DanShen in sera with elevated bilirubin concentrations. We conclude that protein binding of DanShen is lower in uremic sera and in sera with elevated bilirubin concentrations. J. Clin. Lab. Anal. 17:179–183, 2003. © 2003 Wiley‐Liss, Inc.
Keywords: DanShen, uremia, protein binding, hyperbilirubinemia
REFERENCES
- 1. Heck A, Dewitt B, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm 2000;57:1221–1227. [PubMed] [Google Scholar]
- 2. Zhou W, Ruigrok TJC. Protective effects of Danshen during myocardial ischemia and reperfusion: an isolated rat heart study. Am J Chin Med 1990;18:19–24. [DOI] [PubMed] [Google Scholar]
- 3. Chang HM, But PPH, editors. Pharmacology and applications of Chinese materia medica. Singapore: World Scientific Publishing Co.; 1986. p 255. [Google Scholar]
- 4. Li CP, Yung KH, Chiu KW. Hypotensive action of salvia miltiorrhiza cell culture extract. Am J Chin Med 1990;18:157–166. [DOI] [PubMed] [Google Scholar]
- 5. Zhang X, Wu K, et al. The effect of radix salviae miltiorrhizae composite and ligustrazine on lipid peroxidation in low density lipoprotein due to copper dichloride. J Tradit Chin Med 1994;14:292–297. [PubMed] [Google Scholar]
- 6. Lee AR, Wu WL, Chang W, Lin C, King ML. Isolation and bioactivity of new tanshinones. J Nat Prod 1987;50:157–160. [DOI] [PubMed] [Google Scholar]
- 7. Wahed A, Dasgupta A. Positive and negative in vitro interference of Chinese medicine Danshen in serum digoxin measurement: elimination of interference by monitoring free digoxin concentrations. Am J Clin Pathol 2001;116:403–408. [DOI] [PubMed] [Google Scholar]
- 8. Perucca E. Plasma protein binding of phenytoin in health and disease: relevance to therapeutic drug monitoring. Ther Drug Monit 1980;2:173–178. [PubMed] [Google Scholar]
- 9. Gugler R, Azarnoff DL. Drug protein binding and nephritic syndrome. Clin Pharmacokinet 1976;1:25–35. [DOI] [PubMed] [Google Scholar]
- 10. Yuan R, Venitz J. Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs. Int J Clin Pharmacol 2000;38:245–253. [DOI] [PubMed] [Google Scholar]
- 11. Burt M, Anderson D, Kloss J, Apple F. Evidence based implementation of free phenytoin therapeutic drug monitoring. Clin Chem 2000;46:1132–1135. [PubMed] [Google Scholar]
- 12. Zielmann S, Mielck F, Kahl R, et al. A rational basis for the measurement of free phenytoin concentrations in critically ill trauma patients. Ther Drug Monit 1994;16:139–144. [DOI] [PubMed] [Google Scholar]
- 13. Craig WA, Evenson MA, Sarver KP, Wagnild JP. Correction of protein binding defect in uremic serum by charcoal treatment. J Lab Clin Med 1976;87:637–647. [PubMed] [Google Scholar]
- 14. Dasgupta A, Crossey MJ. Elevated free fatty acid concentrations in lipemic sera reduce protein binding of valproic acid significantly more than phenytoin. Am J Med Sci 1997;313:75–79. [DOI] [PubMed] [Google Scholar]
- 15. Stone JA, Soldin SJ. An update on digoxin. Clin Chem 1989;35:1326–1331. [PubMed] [Google Scholar]
- 16. Miller JJ, Straub RW, Valdes R. Analytical performance of a monoclonal digoxin assay with increased specificity on the ACS:180. Ther Drug Monit 1996;18:65–72. [DOI] [PubMed] [Google Scholar]
- 17. Dasgupta A. Endogenous and exogenous digoxin‐like immunoreactive substances: impact on therapeutic drug monitoring [Review]. Am J Clin Pathol 2002;118:132–140. [DOI] [PubMed] [Google Scholar]